Galera Therapeutics, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- J. Mel Sorensen
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2 West Liberty Boulevard Malvern PA United States of America 19355
- IPO Date
- Nov 7, 2019
- CIK
- 0001563577
- Website
- galeratx.com
- Similar Companies
- Business
- Galera Therapeutics, Inc. (GRTX) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting cancer vulnerabilities in tumor cells, immune cells, and the tumor microenvironment, including superoxide dismutase (SOD) mimetics and nitric oxide synthase (NOS) inhibitors. The company offers a pipeline featuring tilarginine, a pan-NOS inhibitor in Phase 1/2 trials combined with standard-of-care nab-paclitaxel and alpelisib for metaplastic breast cancer and refractory triple-negative breast cancer; avasopasem manganese, a SOD mimetic previously studied for radiotherapy-induced toxicities in head and neck and lung cancer patients and now planned for a Phase 1b/2 trial in hormone receptor-positive/HER2-negative advanced breast cancer starting in the first half of 2025; and rucosopasem, another SOD mimetic. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera operates primarily in the United States with academic partnerships including the I-SPY 2 network and NCI grants targeting patients with treatment-resistant advanced breast cancer subtypes. Recent strategic shifts include the completion of its acquisition of Nova Pharmaceuticals in December 2024, pivoting development from toxicity reduction to anti-cancer therapeutics and securing concurrent financing to extend cash runway into 2026; followed by the October 2025 sale of its dismutase mimetics portfolio, including avasopasem and rucosopasem, to Biossil Inc. for up to $105 million in milestones to sharpen focus on the NOS inhibitor program in breast cancer.
GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Galera Therapeutics, Inc. (OTCMKTS: GRTX)
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
Athersys (NASDAQ:ATHX) and Galera Therapeutics (NASDAQ:GRTX) Critical Review
Critical Review: Galera Therapeutics (NASDAQ:GRTX) versus China Pharma (NYSE:CPHI)
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
Galera Announces Board Approval of Complete Liquidation and Dissolution
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
Galera Adopts Limited Duration Stockholder Rights Agreement
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)
All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Galera Therapeutics shares plummet after FDA rejects drug for cancer treatment side effect